



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

RECEIVED

JUL 23 2002

TECH CENTER 1600/2900

IN THE APPLICATION OF: Ko et al. : CASE NO.: PH-7054-A  
SERIAL NO.: 09/981,833 : ART UNIT: 1624  
FILED: October 18, 2001: EXAMINER: Unknown

**FOR: Heterocyclic Piperidines as Modulators of Chemokine Receptor Activity**

**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b). Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

- ( X ) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.
- ( ) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
- ( ) Certification in Accordance with §1.97(e) is set forth below.
- ( ) The fee of **\$240.00** as set forth in §1.17(p) is attached.
- ( ) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of **\$130.00** as set forth in §1.17(i)(1)

Please charge any deficiency or credit any overpayment to Deposit Account No. 193880. There are no listed references which are not in the English language.

**RELATED CASE STATEMENT**

**Attorney Docket #**

PH-7050  
PH-7058  
PH-7150  
PH-7151  
PH-7152  
PH-7153

**App./Patent Number**

09/465,286  
09/465,301  
09/465,948  
09/465,287  
09/466,442  
6,331,541

**Filing/Grant Date**

12/17/1999  
12/17/1999  
12/17/1999  
12/17/1999  
12/17/1999  
12/18/2001

**Status**

Pending  
Pending  
Pending  
Pending  
Pending  
Granted

RECEIVED

JUL 23 2002

TECH CENTER 1600/2900

Respectfully submitted,

*Mary VanAtten*

Mary K. VanAtten  
Attorney for Applicants  
Registration No. 39,408  
Telephone: 302-467-5268

DATE: 7/16/02

Bristol-Myers Squibb Company  
P. O. Box 4000  
Princeton, NJ 08543-4000

**Certificate of Mailing under 37 CFR 1.8**In the Application of: **Ko et al**CASE NO.: **PH-7054-A**APPLICATION NO.: **09/981,833**GROUP ART UNIT: **1624**FILED: **OCTOBER 18, 2001**EXAMINER: **UNKNOWN****FOR: HETEROCYCLIC PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR  
ACTIVITY**

I hereby certify that this correspondence, a Information Disclosure Statement (with 1449 form and references) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Assistant Commissioner for Patents  
Washington, D.C. 20231

on July 17, 2002  
Date

Signature

Denise Bierlein

Type or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

**RECEIVED**

JUL 23 2002

TECH CENTER 1600/2900